Xopenex Hfa is owned by Sunovion.
Xopenex Hfa contains Levalbuterol Tartrate.
Xopenex Hfa has a total of 2 drug patents out of which 0 drug patents have expired.
Xopenex Hfa was authorised for market use on 11 March, 2005.
Xopenex Hfa is available in aerosol, metered;inhalation dosage forms.
Xopenex Hfa can be used as treatment or prevention of bronchospasm or asthmatic symptoms.
The generics of Xopenex Hfa are possible to be released after 08 October, 2024.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7256310||SUNOVION||Levalbuterol salt|| |
(1 year, 6 months from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8765153||SUNOVION||Levalbuterol salt|| |
(8 months from now)
Drugs and Companies using LEVALBUTEROL TARTRATE ingredient
Market Authorisation Date: 11 March, 2005
Treatment: Treatment or prevention of bronchospasm or asthmatic symptoms
Dosage: AEROSOL, METERED;INHALATION
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic